We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Adagene Inc. Sponsored ADR (ADAG - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adagene Inc. Sponsored ADR is a member of the Medical sector. This group includes 888 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Adagene Inc. Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ADAG's full-year earnings has moved 37.3% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, ADAG has moved about 100% on a year-to-date basis. At the same time, Medical stocks have lost an average of 6.6%. This means that Adagene Inc. Sponsored ADR is performing better than its sector in terms of year-to-date returns.
Contineum Therapeutics, Inc. (CTNM - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 14.5%.
In Contineum Therapeutics, Inc.'s case, the consensus EPS estimate for the current year increased 13% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Adagene Inc. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 431 individual companies and currently sits at #146 in the Zacks Industry Rank. On average, this group has lost an average of 2.2% so far this year, meaning that ADAG is performing better in terms of year-to-date returns. Contineum Therapeutics, Inc. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Adagene Inc. Sponsored ADR and Contineum Therapeutics, Inc.. These stocks will be looking to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Adagene (ADAG) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Adagene Inc. Sponsored ADR (ADAG - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adagene Inc. Sponsored ADR is a member of the Medical sector. This group includes 888 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Adagene Inc. Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ADAG's full-year earnings has moved 37.3% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, ADAG has moved about 100% on a year-to-date basis. At the same time, Medical stocks have lost an average of 6.6%. This means that Adagene Inc. Sponsored ADR is performing better than its sector in terms of year-to-date returns.
Contineum Therapeutics, Inc. (CTNM - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 14.5%.
In Contineum Therapeutics, Inc.'s case, the consensus EPS estimate for the current year increased 13% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Adagene Inc. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 431 individual companies and currently sits at #146 in the Zacks Industry Rank. On average, this group has lost an average of 2.2% so far this year, meaning that ADAG is performing better in terms of year-to-date returns. Contineum Therapeutics, Inc. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Adagene Inc. Sponsored ADR and Contineum Therapeutics, Inc.. These stocks will be looking to continue their solid performance.